$594 Million is the total value of VR Adviser, LLC's 28 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 54.8% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $78,863,057 | +80.5% | 2,699,865 | +26.7% | 13.28% | +97.0% |
| ACRS | ACLARIS THERAPEUTICS INC | $71,882,402 | +0.1% | 4,563,962 | 0.0% | 12.11% | +9.2% | |
| AXSM | New | AXSOME THERAPEUTICS INC | $51,732,479 | – | 670,718 | +100.0% | 8.72% | – |
| COGT | COGENT BIOSCIENCES INC | $46,680,633 | -22.5% | 4,038,117 | 0.0% | 7.86% | -15.4% | |
| TERN | TERNS PHARMACEUTICALS INC | $37,746,330 | +72.8% | 3,707,891 | 0.0% | 6.36% | +88.7% | |
| GHRS | Buy | GH RESEARCH PLCordinary shares | $34,186,455 | -11.7% | 3,517,125 | +5.5% | 5.76% | -3.6% |
| CELC | New | CELCUITY INC | $29,496,458 | – | 2,105,386 | +100.0% | 4.97% | – |
| Buy | DICE THERAPEUTICS INC | $25,552,800 | +64.7% | 819,000 | +7.1% | 4.30% | +79.8% | |
| AVTE | Sell | AEROVATE THERAPEUTICS INC | $21,912,562 | +58.5% | 747,869 | -10.3% | 3.69% | +73.0% |
| PLRX | PLIANT THERAPEUTICS INC | $20,876,400 | -7.5% | 1,080,000 | 0.0% | 3.52% | +1.0% | |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $19,716,669 | – | 2,916,667 | +100.0% | 3.32% | – |
| NVAX | New | NOVAVAX INC | $19,325,310 | – | 1,879,894 | +100.0% | 3.26% | – |
| MRUS | New | MERUS N V | $18,969,531 | – | 1,226,214 | +100.0% | 3.20% | – |
| CABA | New | CABALETTA BIO INC | $17,531,386 | – | 1,895,285 | +100.0% | 2.95% | – |
| ANNX | ANNEXON INC | $16,647,659 | -16.3% | 3,220,050 | 0.0% | 2.80% | -8.7% | |
| VECT | New | VECTIVBIO HLDG AG | $16,168,890 | – | 1,866,000 | +100.0% | 2.72% | – |
| PRVB | PROVENTION BIO INC | $11,824,162 | +134.9% | 1,118,653 | 0.0% | 1.99% | +156.4% | |
| SVRA | Buy | SAVARA INC | $9,844,873 | +39.4% | 6,351,531 | +39.4% | 1.66% | +52.2% |
| MIST | Sell | MILESTONE PHARMACEUTICALS IN | $8,746,896 | -60.8% | 2,208,812 | -8.9% | 1.47% | -57.2% |
| Sell | LIANBIOsponsored ads | $7,860,597 | -26.9% | 4,793,047 | -10.9% | 1.32% | -20.2% | |
| Sell | MARINUS PHARMACEUTICALS INC | $7,047,406 | -66.4% | 1,770,705 | -43.9% | 1.19% | -63.4% | |
| TRVI | TREVI THERAPEUTICS INC | $5,886,542 | +25.3% | 3,050,022 | 0.0% | 0.99% | +36.8% | |
| FULC | Sell | FULCRUM THERAPEUTICS INC | $3,256,533 | -66.5% | 447,326 | -62.7% | 0.55% | -63.4% |
| LYRA | LYRA THERAPEUTICS INC | $2,901,894 | -37.3% | 924,170 | 0.0% | 0.49% | -31.5% | |
| INZY | INOZYME PHARMA INC | $2,845,486 | -60.8% | 2,709,987 | 0.0% | 0.48% | -57.3% | |
| LIFE | Sell | ATYR PHARMA INC | $2,565,445 | -38.9% | 1,171,436 | -16.3% | 0.43% | -33.3% |
| AFMD | AFFIMED N V | $1,771,428 | -39.8% | 1,428,571 | 0.0% | 0.30% | -34.4% | |
| RALLYBIO CORP | $1,764,255 | -54.6% | 268,532 | 0.0% | 0.30% | -50.5% | ||
| CLDX | Exit | Celldex Therapeutics Inc | $0 | – | -75,000 | -100.0% | -0.32% | – |
| IMCR | Exit | Immunocore Holdings PLCads | $0 | – | -94,605 | -100.0% | -0.68% | – |
| ALT | Exit | Altimmune Inc | $0 | – | -369,306 | -100.0% | -0.73% | – |
| RXDX | Exit | Prometheus Biosciences Inc | $0 | – | -121,663 | -100.0% | -1.11% | – |
| Exit | Ventyx Biosciences Inc | $0 | – | -207,925 | -100.0% | -1.12% | – | |
| AKUS | Exit | Akouos Inc | $0 | – | -2,800,566 | -100.0% | -2.92% | – |
| TIL | Exit | Instil Bio Inc | $0 | – | -4,105,779 | -100.0% | -3.07% | – |
| GOSS | Exit | Gossamer Bio Inc | $0 | – | -1,747,000 | -100.0% | -3.23% | – |
| RLMD | Exit | Relmada Therapeutics Inc | $0 | – | -1,518,056 | -100.0% | -8.67% | – |
| TCDA | Exit | Tricida Inc | $0 | – | -9,050,064 | -100.0% | -14.64% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ACLARIS THERAPEUTICS INC | 12 | Q3 2023 | 12.7% |
| VIRIDIAN THERAPEUTICS INC | 12 | Q3 2023 | 13.4% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.3% |
| RELMADA THERAPEUTICS INC | 11 | Q3 2022 | 9.9% |
| GH RESEARCH PLC | 10 | Q3 2023 | 6.7% |
| ALTIMMUNE INC | 9 | Q3 2022 | 11.6% |
| MARINUS PHARMACEUTICALS INC | 9 | Q4 2022 | 5.7% |
| CELLDEX THERAPEUTICS INC | 9 | Q3 2022 | 7.6% |
| AFFIMED N V | 8 | Q3 2023 | 1.1% |
| INSTIL BIO INC | 7 | Q3 2022 | 18.7% |
View VR Adviser, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR/A | 2023-05-15 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View VR Adviser, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.